NKGN (NKGen Biotech) ROE % Adjusted to Book Value: Negative Equity% (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is NKGen Biotech ROE % Adjusted to Book Value?

NKGen Biotech NKGN ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2025.

NKGen Biotech's ROE % for the quarter that ended in Mar. 2025 was Negative Equity. NKGen Biotech's PB Ratio for the quarter that ended in Mar. 2025 was N/A. NKGen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 was Negative Equity.

NKGen Biotech ROE % Adjusted to Book Value Related Terms

NKGen Biotech ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for NKGen Biotech's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech ROE % Adjusted to Book Value Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
0.00 0.00 0.00 0.00

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 Negative Equity 0.00 Negative Equity

NKGN vs CALC, CLGN, MBRX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, NKGen Biotech's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's ROE % Adjusted to Book Value falls into.


NKGen Biotech ROE % Adjusted to Book Value Calculation

NKGen Biotech's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

NKGen Biotech's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=Negative Equity / N/A
=Negative Equity

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of Negative Equity% mean?
NKGen Biotech (NKGN) has a ROE % Adjusted to Book Value of Negative Equity% as of Mar. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NKGen Biotech and its competitors.
Is NKGen Biotech's ROE % Adjusted to Book Value too high?
NKGen Biotech's current ROE % Adjusted to Book Value is Negative Equity%.
How does NKGen Biotech's ROE % Adjusted to Book Value compare to CALC and CLGN?
NKGen Biotech's ROE % Adjusted to Book Value of Negative Equity% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on NKGen Biotech and its competitors. NKGen Biotech's current ROE % Adjusted to Book Value is Negative Equity%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NKGen Biotech stock overvalued right now?
NKGen Biotech (NKGN) has a current ROE % Adjusted to Book Value of Negative Equity%. The current ROE % Adjusted to Book Value is Negative Equity%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For NKGen Biotech (NKGN), the current ROE % Adjusted to Book Value is Negative Equity% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NKGen Biotech Business Description

Address 3001 Daimler Street, Santa Ana, CA, USA, 92705
NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.